Citric acid effects on brain and liver oxidative stress in lipopolysaccharide-treated mice

Journal of Medicinal Food

Volumn 17, Issue 5, 2014, Pages 588-598

  Abdel Salam, Omar M E ^a   Youness, Eman R ^a   Mohammed, Nadia A ^a   Morsy, Safaa M Youssef ^a   Omara, Enayat A ^a   Sleem, Amany A ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

antioxidant activity; citric acid; cytokines; dietary supplementation; peripheral infection; systemic inflammation

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CITRIC ACID; ENDOTOXIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MALONALDEHYDE; NITRITE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN TISSUE; CITRUS FRUIT; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; INFLAMMATION; LIPID PEROXIDATION; LIVER; LIVER INJURY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BRAIN; BRAIN LEVEL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; LIVER DISEASES; METABOLISM; PERITONEUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BRAIN; BRAIN CHEMISTRY; CASPASE 3; CITRIC ACID; DNA FRAGMENTATION; GLUTATHIONE PEROXIDASE; INFLAMMATION; LIPID PEROXIDATION; LIPOPOLYSACCHARIDES; LIVER; LIVER DISEASES; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; OXIDATIVE STRESS; PERITONEUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900534836     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.0065     Document Type: Article

References (53)

1. Halliwell B: Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-1623.
2. Halliwell B: Biochemistry of oxidative stress. Biochem Soc Trans 2007; 35: 1147-1150.
3. Wickens AP: Ageing and the free radical theory. Respir Physiol 2001; 128: 379-391.
4. Gutteridge JMC: Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819-1828.
5. Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291-295.
6. Halliwell N: Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001; 18: 685-716.
7. Valko M, Leibfritz D, Moncol J, et al.: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
8. Sayre LM, Perry G, Smith MA: Oxidative stress and neurotoxicity. Chem Res Toxicol 2008; 21: 172-188.
9. Penniston KL, Nakada SY, Holmes RP, et al.: Quantitative assessment of citric acid in lemon juice, lime juice, and commercially- available fruit juice products. J Endourol 2008; 22: 567-570.
10. Grigor JMV, Johnson WS, Salminen S: Food additives for special dietary purposes. In: Food Additives, 2nd edition. (Branen AL, Davidson PM, Salminen S, Thorngate JH 3rd, eds.) Marcel Dekker, Inc., Basel, New York, 2002, pp. 341.
11. Gabutti L, Ferrari N, Mombelli G, et al.: The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004; 17: 819-825.
12. Gritters M, Grooteman MP, Schoorl M, et al.: Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153-159.
13. Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, et al.: Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial 2011; 15: 556-564.
14. Bryland A, Wieslander A, Carlsson O, et al.: Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions. Diab Vasc Dis Res 2012; 9: 42-51.
15. Abdel Salam OME, Sleem AA, Shaffie NM: Hepatoprotective effects of citric acid and aspartame on carbon tetrachlorideinduced hepatic damage in rats. EXCLI J 2009; 8: 41-49.
16. Raetz CR, Whitfield C: Lipopolysaccharide endotoxin. Annu Rev Biochem 2002; 71: 635-700.
17. Qin L, Wu X, Block ML, et al.: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55: 453-462.
18. Buttini M, Mir A, Appel K, et al.: Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: Inhibition by methylprednisolone and by rolipram. Br J Pharmacol 1997; 122: 1483-1489.
19. Turrin NP, Gayle D, Ilyin SE, et al.: Pro-inflammatory and antiinflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull 2001; 54: 443-453.
20. Fiorucci S, Mencarelli A, Meneguzzi A, et al.: NCX-4016 (NOAspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo. Role of nitric oxide. Circulation 2002; 106: 3120-3125.
21. Ruiz-Larrea MB, Leal AM, Liza M, et al.: Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids 1994; 59: 383-388.
22. Ellman GL: Tissue sulfhydryl groups. Arch Biochem 1959; 82: 70-77.
23. Moshage H, Kok B, Huizenga JR: Nitrite and nitrate determination in plasma: a critical evaluation. Clin Chem 1995; 41: 892-896.
24. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
25. Higashino K, Takahashi Y, Yamamura Y: Release of phenyl acetate esterase from liver microsomes by carbon tetrachloride. Clin Chim Acta 1972; 41: 313-320.
26. Watson AD, Berliner JA, Hama SY, et al.: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
27. Chen W, Jin W, Cook M, et al.: Oral delivery of group a streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. J Immunol 1998; 161: 6297-6304.
28. Gercel-Taylor C: Diphenylamine assay of DNA fragmentation for chemosensitivity testing. Methods Mol Med 2005; 111: 79-82.
29. Crowley LV: The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin Chem 1967; 13: 482-487.
30. Belfield A, Goldberg DM: Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 1971; 12: 561-573.
31. Gown AM, Willingham MC: Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase
32. J Histochem Cytochem 2002; 50: 449-454.
33. Dawson TM, Snyder SH: Gases as biological messengers: Nitric oxide and carbon monoxide in the brain. J Neurosci 1994; 14: 5147-5159.
34. Förstermann U, Sessa WC: Nitric oxide synthases: Regulation and function. Eur Heart J 2012; 33: 829-837.
35. Bal-Price A, Brown GC: Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001; 21: 6480-6491.
36. Beckman JS: The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol 1991; 15: 53-59.
37. Moncada S, Bolanos JP: Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006; 97: 1676-1689.
38. Feueurstein G, Liu T, Barone F: Cytokines, inflammation and brain injury: role of TNF alpha. Cerebrovasc Brain Metab Rev 1994; 6: 341-360.
39. Tansey MG, Wyss-Coray T: Cytokines in CNS inflammation and disease. In: Central Nervous System Diseases and Inflammation. (Lane TE, Carson M, Bergmann C, Wyss-Coray T, eds.) Springer, New York, 2008, pp. 59-106.
40. Tweedie D, Sambamurti K, Greig NH: TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 2007; 4: 378-385.
41. McCoy MK, Tansey MG: TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflamm 2008; 5: 45.
42. Frankola KA, Greig NH, Luo W, et al.: Targeting TNF-a to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets 2011; 10: 391-403.
43. Goehler LE, Gaykema RP, Hansen MK, et al.: Vagal immune-tobrain communication: a visceral chemosensory pathway. Auton Neurosci 2000; 85: 49-59.
44. Romanovsky AA: Signaling the brain in the early sickness syndrome: are sensory nerves involved? Front Biosci 2004; 9: 494-504.
45. Bjarnason I, Smethurst P, Macpherson A, et al.: Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992; 102: 1546-1550.
46. Caudarella R, Vescini F, Buffa A, et al.: Citrate andmineral metabolism: kidney stones and bone disease. Front Biosci 2003; 8: s1084-s1106.
47. German JB: Antioxidants. In: Food Additives, 2nd edition. (Branen AL, Davidson PM, Salminen S, Thorngate JH 3rd, eds.) Marcel Dekker, Inc., Basel, New York, 2002, pp. 538.
48. Palozza P: Evidence for pro-oxidant effects of carotenoids in vitro and in vivo implications in health and disease. In: Carotenoids in Health and Disease. (Mayne ST, Sies H, Krinsky NI, eds.) CRC Press, Marcel Dekker AG, New York, 2004, pp. 127-149.
49. Bowry VW, Stocker R: Tocopherol-mediated peroxidation. The prooxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein. J Am Chem Soc 1993; 115: 6029-6044.
50. Podmore ID, Griffiths HR, Herbert KE, et al.: Vitamin C exhibits pro-oxidant properties. Nature 1998; 392: 559.
51. Bouayed J, Bohn T: Exogenous antioxidants-double-edged swords in cellular redox state. Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev 2010; 3: 228-237.
52. Kang DE, Sur RL, Haleblian GE, et al.: Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol 2007; 177: 1358-1362.
53. Haleblian GE, Leitao VA, Pierre SA, et al.: Assessment of citrate concentrations in citrus fruit-based juices and beverages: implications for management of hypocitraturic nephrolithiasis. J Endourol 2008; 22: 1359-1366.